Dyne Therapeutics Files Q1 2025 10-Q

Ticker: DYN · Form: 10-Q · Filed: May 8, 2025 · CIK: 1818794

Dyne Therapeutics, INC. 10-Q Filing Summary
FieldDetail
CompanyDyne Therapeutics, INC. (DYN)
Form Type10-Q
Filed DateMay 8, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, financials, biotech

TL;DR

Dyne Therapeutics filed its Q1 2025 10-Q. Financials and business updates inside.

AI Summary

Dyne Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business activities. Key financial data and operational details are included in this filing.

Why It Matters

This filing provides investors with the latest financial health and operational status of Dyne Therapeutics, crucial for understanding its ongoing development and market position.

Risk Assessment

Risk Level: medium — As a biopharmaceutical company, Dyne Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 10-Q filing?

The reporting period is for the quarter ended March 31, 2025.

When was this 10-Q filed with the SEC?

This 10-Q was filed on May 8, 2025.

What is Dyne Therapeutics, Inc.'s fiscal year end?

Dyne Therapeutics, Inc.'s fiscal year ends on December 31.

What is the company's primary business address?

The company's business address is 1560 TRAPELO ROAD, WALTHAM, MA 02451.

What is the SEC file number for Dyne Therapeutics, Inc.?

The SEC file number is 001-39509.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Dyne Therapeutics, Inc. (DYN).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing